Kimberly-Clark (CHIX:KMYD) Beta: N/A (As of Jun. 24, 2026)


CHIX:KMYD Kimberly-Clark Corp CHIX:KMYD
56 GF Score
Price €90.47
GF Value €108.12
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Kimberly-Clark Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Kimberly-Clark's Beta is Not available.

Kimberly-Clark  (CHIX:KMYd) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Kimberly-Clark Beta Related Terms

Kimberly-Clark Beta Historical Data

* Premium members only.

The historical data trend for Kimberly-Clark's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kimberly-Clark Beta Chart

Kimberly-Clark Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kimberly-Clark Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:KMYD
56GF Score
Kimberly-Clark Corp CHIX:KMYD
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kimberly-Clark Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Kimberly-Clark (CHIX:KMYD) Overvalued in 2026?

Based on GuruFocus' analysis, Kimberly-Clark stock appears to be undervalued. The current stock price of €90.47 is trading 16.3% below its estimated GF Value™ of €108.12. GuruFocus considers Kimberly-Clark to be Modestly Undervalued.

Key valuation signals for CHIX:KMYD:

  • Beta: N/A
  • GF Value™: €108.12 vs. price of €90.47 (16.3% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the CHIX:KMYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kimberly-Clark Business Description

Address P.O. Box 619100, Dallas, TX, USA, 75261-9100
With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide workplace safety and sanitation solutions. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America. It is slated to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026.
56GF Score

Get the complete analysis for CHIX:KMYD

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€90.47
Price
€108.12
GF Value